CP and myeloproliferative disorder: The therapeutic efficacy of USP5@Exosome-CP was assayed in MPN mice model (Fig. 6A), and the therapeutic process is depicted in Fig. 6B. The therapeutic concentration used in in vivo experiments was 5 mg/kg USP5-IN-1 (equivalent to 50 mg/kg exosome particles per mouse).